DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE | N209091 | ASTRAZENECA AB
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AstraZeneca AB v. Sun Pharmaceutical Industries Limited et al 1 patentANDA 211492dapagliflozin/saxagliptin hydrochloride | D. Del. | 2023-12-04 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 6515117 | Oct 4, 2025PED: Apr 4, 2026 | PED | Yes | Yes | — | |
| 7919598 | Dec 16, 2029PED: Jun 16, 2030 | PED | Yes | — | — | — |
| 8221786 | Mar 21, 2028PED: Sep 21, 2028 | PED | — | Yes | — | — |
| 8361972 | Mar 21, 2028PED: Sep 21, 2028 | PED | — | — | — | |
| 8501698 | Jun 20, 2027PED: Dec 20, 2027 | PED | — | Yes | — | |
| 8716251 | Mar 21, 2028PED: Sep 21, 2028 | PED | — | Yes | — | — |